Leflunomide
- Generic Name
- Leflunomide
- Brand Names
- Arava, Leflunomide medac, Leflunomide Zentiva (previously Leflunomide Winthrop), Leflunomide ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 75706-12-6
- Unique Ingredient Identifier
- G162GK9U4W
- Background
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
- Indication
For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
- Associated Conditions
- Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis
- Associated Therapies
- -
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03952832
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
The Registry Study of Takayasu Arteritis in East China
- Conditions
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT03893136
- Locations
- 🇨🇳
Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai, Shanghai, China
Psoriatic Oligoarthritis Intervention With Symptomatic thErapy
- Conditions
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 1
- Registration Number
- NCT03797872
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 315
- Registration Number
- NCT03739853
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Joseph Sparano
- Target Recruit Count
- 54
- Registration Number
- NCT03709446
- Locations
- 🇺🇸
Mt Sinai Chelesa, New York, New York, United States
🇺🇸Mt Sinai West, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2021-07-27
- Target Recruit Count
- 136
- Registration Number
- NCT02930343
- Locations
- 🇮🇳
Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India
Leflunomide for Maintenance of Remission in IgG4 Related Disease
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT02703194
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2019-10-01
- Target Recruit Count
- 186
- Registration Number
- NCT02644499
- Locations
- 🇮🇳
Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, Pondicherry UT, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.